|
健保碼及健保價 |
|
See related Vincristine Sulphate DBL inj "Hospira"[文克斯汀 注射劑] information |
|
|
|
製造商 |
Hospira |
|
代理/經銷商 |
Hospira |
|
成份 |
Vincristine sulfate |
|
適應症 |
Acute leukemia. |
|
用量 |
Administer at weekly intervals. Adult 0.4-1.4 mg/m2 body surface area (BSA). Children >10 kg or >1 m2 BSA 1.5-2 mg/m2 BSA, ≤10 kg or ≤1 m2 BSA 0.05 mg/kg. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Demyelinating form of Charcot-Marie-Tooth syndrome. Intrathecal administration. |
|
注意事項 |
Preexisting neuromuscular disease. Hepatic impairment. Elderly. Leucopenia or complicating infection. Avoid extravasation. |
|
不良反應 |
Impaired walking, convulsions, HTN, constipation, abdominal pain, acute uric acid nephropathy, alopecia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Vincristine Sulphate DBL 注射劑 |
|
Vincristine Sulphate DBL 1 mg/1 mL x 1 mL |
|
|
|
Manufacturer: |
Hospira |
|
Distributor: |
Hospira |
|
 |
|
|
|
